These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 27025703

  • 1. Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors.
    Chatelle CV, Hövermann D, Müller A, Wagner HJ, Weber W, Radziwill G.
    Sci Rep; 2016 Mar 30; 6():23713. PubMed ID: 27025703
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
    Peng SB, Henry JR, Kaufman MD, Lu WP, Smith BD, Vogeti S, Rutkoski TJ, Wise S, Chun L, Zhang Y, Van Horn RD, Yin T, Zhang X, Yadav V, Chen SH, Gong X, Ma X, Webster Y, Buchanan S, Mochalkin I, Huber L, Kays L, Donoho GP, Walgren J, McCann D, Patel P, Conti I, Plowman GD, Starling JJ, Flynn DL.
    Cancer Cell; 2015 Sep 14; 28(3):384-98. PubMed ID: 26343583
    [Abstract] [Full Text] [Related]

  • 3. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
    Wang H, Quan H, Lou L.
    Biochem Biophys Res Commun; 2017 Jul 15; 489(1):14-20. PubMed ID: 28536078
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
    Basile KJ, Le K, Hartsough EJ, Aplin AE.
    Pigment Cell Melanoma Res; 2014 May 15; 27(3):479-84. PubMed ID: 24422853
    [Abstract] [Full Text] [Related]

  • 5. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.
    Krayem M, Journe F, Wiedig M, Morandini R, Sales F, Awada A, Ghanem G.
    Eur J Cancer; 2014 May 15; 50(7):1310-20. PubMed ID: 24559688
    [Abstract] [Full Text] [Related]

  • 6. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N.
    Nature; 2010 Mar 18; 464(7287):427-30. PubMed ID: 20179705
    [Abstract] [Full Text] [Related]

  • 7. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF.
    Oncotarget; 2017 Feb 07; 8(6):9251-9266. PubMed ID: 27999210
    [Abstract] [Full Text] [Related]

  • 8. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G, Artuso S, De Luca A, Muzi A, Rotili D, Scimeca M, Atzori MG, Ceci C, Mai A, Leonetti C, Levati L, Bonanno E, Tentori L, Caccuri AM.
    Biochem Pharmacol; 2015 May 01; 95(1):16-27. PubMed ID: 25795251
    [Abstract] [Full Text] [Related]

  • 9. BRAF Inhibitors and Radiation Do Not Act Synergistically to Inhibit WT and V600E BRAF Human Melanoma.
    Walter L, Heinzerling L.
    Anticancer Res; 2018 Mar 01; 38(3):1335-1341. PubMed ID: 29491057
    [Abstract] [Full Text] [Related]

  • 10. The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phospho-Ser-621 in the C terminus of CRAF.
    Yuan J, Ng WH, Yap J, Chia B, Huang X, Wang M, Hu J.
    J Biol Chem; 2018 Sep 14; 293(37):14276-14284. PubMed ID: 30030377
    [Abstract] [Full Text] [Related]

  • 11. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
    Su F, Bradley WD, Wang Q, Yang H, Xu L, Higgins B, Kolinsky K, Packman K, Kim MJ, Trunzer K, Lee RJ, Schostack K, Carter J, Albert T, Germer S, Rosinski J, Martin M, Simcox ME, Lestini B, Heimbrook D, Bollag G.
    Cancer Res; 2012 Feb 15; 72(4):969-78. PubMed ID: 22205714
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
    Del Curatolo A, Conciatori F, Cesta Incani U, Bazzichetto C, Falcone I, Corbo V, D'Agosto S, Eramo A, Sette G, Sperduti I, De Luca T, Marabese M, Shirasawa S, De Maria R, Scarpa A, Broggini M, Del Bufalo D, Cognetti F, Milella M, Ciuffreda L.
    J Exp Clin Cancer Res; 2018 Jul 09; 37(1):140. PubMed ID: 29986755
    [Abstract] [Full Text] [Related]

  • 13. LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
    Monaco KA, Delach S, Yuan J, Mishina Y, Fordjour P, Labrot E, McKay D, Guo R, Higgins S, Wang HQ, Liang J, Bui K, Green J, Aspesi P, Ambrose J, Mapa F, Griner L, Jaskelioff M, Fuller J, Crawford K, Pardee G, Widger S, Hammerman PS, Engelman JA, Stuart DD, Cooke VG, Caponigro G.
    Clin Cancer Res; 2021 Apr 01; 27(7):2061-2073. PubMed ID: 33355204
    [Abstract] [Full Text] [Related]

  • 14. SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor.
    Kaplan FM, Kugel CH, Dadpey N, Shao Y, Abel EV, Aplin AE.
    J Biol Chem; 2012 Dec 07; 287(50):41797-807. PubMed ID: 23076151
    [Abstract] [Full Text] [Related]

  • 15. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
    Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J.
    Cancer Res; 2008 Jun 15; 68(12):4853-61. PubMed ID: 18559533
    [Abstract] [Full Text] [Related]

  • 16. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R.
    Pharmacol Res; 2018 Sep 15; 135():239-258. PubMed ID: 30118796
    [Abstract] [Full Text] [Related]

  • 17. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
    Henry JR, Kaufman MD, Peng SB, Ahn YM, Caldwell TM, Vogeti L, Telikepalli H, Lu WP, Hood MM, Rutkoski TJ, Smith BD, Vogeti S, Miller D, Wise SC, Chun L, Zhang X, Zhang Y, Kays L, Hipskind PA, Wrobleski AD, Lobb KL, Clay JM, Cohen JD, Walgren JL, McCann D, Patel P, Clawson DK, Guo S, Manglicmot D, Groshong C, Logan C, Starling JJ, Flynn DL.
    J Med Chem; 2015 May 28; 58(10):4165-79. PubMed ID: 25965804
    [Abstract] [Full Text] [Related]

  • 18. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.
    Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, Saborowski M, Kastenhuber E, Fellmann C, Ohara K, Morikami K, Miura T, Lukacs C, Ishii N, Lowe S, Rosen N.
    Cancer Cell; 2014 May 12; 25(5):697-710. PubMed ID: 24746704
    [Abstract] [Full Text] [Related]

  • 19. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas.
    Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, Kellet M, Storm PB, Resnick AC.
    Proc Natl Acad Sci U S A; 2013 Apr 09; 110(15):5957-62. PubMed ID: 23533272
    [Abstract] [Full Text] [Related]

  • 20. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-RafV600E inhibitors.
    Wang GM, Wang X, Zhu JM, Guo BB, Yang Z, Xu ZJ, Li B, Wang HY, Meng LH, Zhu WL, Ding J.
    Acta Pharmacol Sin; 2017 Jul 09; 38(7):1059-1068. PubMed ID: 28414204
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.